FDA approves combination therapy of tremelimumab, durvalumab, and platinum-based chemotherapy for metastatic NSCLC
The U.S. Food and Drug Administration (FDA) have approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small…
New research elucidates how air pollution causes lung cancer in never-smokers
Research presented at the European Society of Medical Oncology (ESMO) Congress 2022 has uncovered a non-mutagenic mechanism by which air…
Top picks from WCLC 2022: NADIM II, IMpower010, CALGB 140503, YESS
VJOncology are thrilled to present our top picks from the the IASLC 2022 World Conference on Lung Cancer (WCLC) congress!
Highlights from ASCO 2022
VJOncology are excited to present our top picks from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting!
FDA approves mobocertinib for NSCLC with EGFR exon 20 insertion mutations
The U.S. Food and Drug Administration (FDA) has granted accelerated approval of mobocertinib for patients with metastatic non-small cell lung…
Top 5 in lung from ASCO 2021
Highlights from ASCO 2021 in lung cancer! Learn more about the major clinical trials reported at this year’s meeting.
Top picks from ASCO 2021
VJOncology presents highlights from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!
WCLC 2021 Highlights
VJOncology are pleased to bring you our top picks from the recent virtual WCLC meeting
First-line therapy with TKIs in NSCLC
Advances in treatment options for anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) have improved patient outcomes considerably in…
ADAURA: osimertinib demonstrates significant clinical benefit in adjuvant NSCLC therapy
The first interim results of the Phase III ADAURA study evaluating adjuvant osimertinib in stage IB-IIIA EGFR-mutated non-small cell lung…
Multi-cancer detection and localization for more than 50 cancer types
The early detection of cancer improves outcomes for patients – in terms of both reducing treatment burden and improving the…
Use of pembrolizumab in patients with PS2 NSCLC
Clinical trials assessing the efficacy of pembrolizumab have previously enrolled patients with performance status (PS) 0–1. However, almost a fifth…